Principal Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$908K Buy
7,111
+160
+2% +$20K 0.01% 754
2025
Q4
$847K Sell
6,951
-169
-2% -$19.4K 0.01% 752
2025
Q3
$713K Sell
7,120
-293
-4% -$26.4K 0.01% 774
2025
Q2
$615K Sell
7,413
-4,762
-39% -$380K 0.01% 775
2025
Q1
$1.1M Buy
12,175
+69
+0.6% +$6.17K 0.02% 522
2024
Q4
$1.09M Buy
12,106
+3,325
+38% +$322K 0.02% 522
2024
Q3
$868K Buy
8,781
+454
+5% +$44.6K 0.02% 573
2024
Q2
$772K Buy
8,327
+2,418
+41% +$217K 0.02% 554
2024
Q1
$561K Sell
5,909
-483
-8% -$44.8K 0.02% 621
2023
Q4
$571K Buy
+6,392
New +$475K 0.02% 552

Other funds holding XBI

Principal Securities's XBI Position: Q1 2026 in Review

Principal Securities increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.3% in Q1 2026, buying an estimated $20K and bringing the position to 7,111 shares worth $908K. The position accounts for 0.01% of the portfolio, ranked #754.

Principal Securities first reported a position in XBI in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.1M in Q1 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Principal Securities held 7,111 shares of State Street SPDR S&P Biotech ETF worth $908K as of Q1 2026.
  • Principal Securities bought 160 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $20K.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Principal Securities's portfolio in Q1 2026, its #754 holding.
  • Principal Securities first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 10 quarters since.
  • Principal Securities's State Street SPDR S&P Biotech ETF position peaked at $1.1M in Q1 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.